We are disappointed in Glenmarks decision to introduce products that directly infringe upon our intellectual property, said an MSD spokesperson in an email reply. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them.
Glenmark, which recently launched its low-cost version of the drug, has, however, maintained that its products Zita and Zita-Met are branded generics and were launched after due diligence.
In a reply to FEs query, the company said, Glenmark is a responsible company and has launched the products after due diligence and research.
In India, there are about 60-65 million people with type 2 diabetes. Januvia and Janumet are once-daily prescription pills.